Drug Used to Treat Insomnia Shows Promise in Protecting Against Neurodegenerative Diseases
A recent study has revealed that a drug commonly used to treat insomnia may have the potential to protect against the buildup of abnormal tau protein, a hallmark feature of neurodegenerative diseases such as Alzheimer’s. This discovery opens up new possibilities for developing therapies that could slow down the progression of these devastating conditions.
According to the Alzheimer’s International Federation, nearly 10 million new cases of dementia are reported worldwide each year, highlighting the urgent need for effective treatment options. Despite years of research, there are limited interventions that offer significant benefits to individuals suffering from cognitive decline.
Researchers at Washington University, led by neurologist Samira Parhizkar, explored the potential of a central nervous system depressant called lemborexant, which was approved by the FDA as a sleep aid in December 2019. The team found that this drug not only improved sleep quality but also reduced the abnormal tau protein levels, which are believed to contribute to the neurological damage observed in Alzheimer’s and related disorders.
While amyloid beta proteins have long been associated with Alzheimer’s disease, tau proteins have emerged as another key player in the pathology of the condition. Abnormal tau proteins have been linked to accelerated brain atrophy in animal models, underscoring their significance in disease progression.
Dr. David Holtzman, a neurologist at Washington University, emphasized the importance of targeting abnormal tau accumulation in neurodegenerative diseases. He noted that current treatments focusing on amyloid proteins have limitations in slowing down disease progression, highlighting the need for alternative strategies such as addressing tau pathology.
In a surprising turn of events, the researchers found that lemborexant outperformed another sleep aid, zolpidem, in protecting against memory loss in mice. Mice treated with lemborexant showed up to 40% more volume in their hippocampus, a brain region crucial for memory formation, compared to those receiving zolpidem or no treatment at all.
The protective effects of lemborexant were attributed to its ability to block orexin, a neuropeptide involved in regulating the sleep-wake cycle. Genetic manipulation of orexin receptors in mice resulted in reduced tau protein accumulation, further highlighting the potential of targeting this pathway in neurodegenerative diseases.
Although the study showed promising results in male mice, further research is needed to understand the drug’s efficacy in females and its long-term effects in humans. Lemborexant is currently approved for short-term use in humans, necessitating additional studies to evaluate its impact on tau reduction and disease progression.
Published in Nature Neuroscience, this groundbreaking research offers hope for the development of innovative therapies that could potentially delay the onset and progression of neurodegenerative disorders.
